RETA [NASD]
Reata Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-8.35 Insider Own0.90% Shs Outstand36.41M Perf Week17.28%
Market Cap1.01B Forward P/E- EPS next Y-7.66 Insider Trans5.34% Shs Float30.27M Perf Month-2.14%
Income-303.80M PEG- EPS next Q-2.03 Inst Own86.40% Short Float16.79% Perf Quarter11.64%
Sales11.50M P/S87.77 EPS this Y-2.20% Inst Trans0.99% Short Ratio7.66 Perf Half Y-68.25%
Book/sh3.51 P/B8.20 EPS next Y12.70% ROA-41.60% Target Price59.00 Perf Year-74.21%
Cash/sh15.17 P/C1.90 EPS next 5Y- ROE-137.50% 52W Range20.24 - 153.41 Perf YTD9.14%
Dividend- P/FCF- EPS past 5Y- ROI-131.30% 52W High-81.69% Beta1.18
Dividend %- Quick Ratio12.30 Sales past 5Y-25.40% Gross Margin- 52W Low38.84% ATR2.52
Employees346 Current Ratio12.30 Sales Q/Q0.00% Oper. Margin- RSI (14)51.89 Volatility9.41% 9.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.80% Profit Margin- Rel Volume0.36 Prev Close28.78
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume663.16K Price28.09
Recom1.80 SMA209.32% SMA50-8.79% SMA200-53.50% Volume42,973 Change-2.38%
Mar-24-22Resumed Goldman Buy $91
Dec-09-21Downgrade SVB Leerink Outperform → Mkt Perform $35
Dec-09-21Downgrade Robert W. Baird Outperform → Neutral $110 → $37
May-24-21Initiated Goldman Buy $236
Apr-26-21Initiated Barclays Overweight $155
Jul-10-20Resumed Stifel Buy $315 → $280
Jun-17-20Initiated BTIG Research Buy $237
Nov-13-19Downgrade National Securities Buy → Neutral
Sep-26-19Initiated National Securities Buy $130
Sep-25-18Reiterated Leerink Partners Outperform $116 → $139
Sep-13-17Initiated Leerink Partners Outperform $43
Jul-25-17Reiterated Citigroup Buy $39 → $87
Apr-13-17Initiated Ladenburg Thalmann Buy $55
Feb-23-17Initiated Stifel Buy $38
Jan-25-17Initiated Robert W. Baird Outperform $43
Jun-20-16Initiated Piper Jaffray Overweight $33
Jun-20-16Initiated Citigroup Buy
May-15-22 09:13AM  
May-10-22 10:45AM  
07:55AM  
06:40AM  
May-09-22 08:25AM  
May-02-22 04:31PM  
Apr-04-22 08:59PM  
10:04AM  
Apr-01-22 04:02PM  
Mar-31-22 04:55PM  
Mar-30-22 11:30AM  
07:21AM  
Feb-28-22 12:35PM  
08:19AM  
08:05AM  
06:45AM  
06:09AM  
Feb-25-22 05:30PM  
Feb-21-22 03:01PM  
Feb-18-22 06:45AM  
Feb-08-22 01:38PM  
Feb-07-22 01:38PM  
Feb-03-22 05:38PM  
Feb-02-22 12:16PM  
Jan-31-22 06:45AM  
Jan-20-22 05:38PM  
Jan-11-22 02:35PM  
Jan-05-22 08:57PM  
Dec-31-21 03:40PM  
02:30PM  
02:30PM  
09:01AM  
Dec-30-21 10:00PM  
06:03PM  
06:00PM  
04:29PM  
04:00PM  
03:40PM  
12:45PM  
10:30AM  
Dec-29-21 06:58PM  
06:03PM  
05:15PM  
05:00PM  
04:19PM  
03:50PM  
03:30PM  
12:30PM  
11:25AM  
11:00AM  
09:57AM  
08:00AM  
Dec-28-21 06:03PM  
04:30PM  
03:40PM  
02:29PM  
12:00PM  
11:00AM  
10:30AM  
08:00AM  
Dec-27-21 05:59PM  
02:35PM  
01:45PM  
12:20PM  
12:00PM  
11:20AM  
11:20AM  
11:00AM  
Dec-26-21 10:25PM  
05:30PM  
12:00PM  
08:17AM  
Dec-24-21 06:13PM  
03:16PM  
02:30PM  
12:00PM  
11:00AM  
Dec-23-21 10:15PM  
09:34PM  
05:59PM  
04:05PM  
03:36PM  
01:45PM  
01:30PM  
11:00AM  
10:10AM  
10:00AM  
09:50AM  
Dec-22-21 09:00PM  
08:59PM  
05:15PM  
04:29PM  
01:15PM  
12:15PM  
10:36AM  
10:00AM  
Dec-21-21 10:36PM  
09:00PM  
06:03PM  
05:03PM  
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Soni Manmeet SinghCOO and CFODec 31Buy26.2216,000419,56519,000Jan 04 08:51 AM
Meyer Colin JohnChief Research OfficerJun 15Sale141.8540,0005,673,88117,000Jun 16 04:04 PM
Meyer Colin JohnChief Research OfficerJun 14Sale144.0520,0002,881,02457,000Jun 16 04:04 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 09Sale141.908,4541,199,63014,546Jun 09 04:28 PM
Castellanos ElaineVP, Chief Accounting OfficerJun 07Sale146.751,546226,88314,546Jun 09 04:28 PM
Castellanos ElaineVP, Chief Accounting OfficerMay 26Sale124.5510,0001,245,47014,546May 27 06:15 PM